Last updated: August 7, 2026
VOSEVI is a fixed-dose, film-coated tablet containing sofosbuvir, velpatasvir, and voxilaprevir. Its excipient system is conventional but commercially relevant because the formulation must support three active ingredients with different physicochemical properties, high-dose loading, oral stability, and consistent dissolution. The strongest opportunities are in functional excipients, direct-compression systems, coating materials, analytical support, and generic-development services rather than in commodity excipient supply alone.
What is VOSEVI and how is it formulated?
VOSEVI is manufactured by Gilead Sciences for adults with chronic hepatitis C virus infection, including patients with prior direct-acting antiviral treatment experience. Each tablet contains:
| Component |
Amount per tablet |
| Sofosbuvir |
400 mg |
| Velpatasvir |
100 mg |
| Voxilaprevir |
100 mg |
| Total active pharmaceutical ingredient load |
600 mg |
The product was approved by the U.S. Food and Drug Administration on July 18, 2017. It is administered once daily with food for specified treatment durations, depending on prior treatment history and cirrhosis status. The food requirement has direct formulation and commercial implications because excipients and manufacturing controls must preserve dissolution and exposure across a clinically relevant fed-state window.[1]
What inactive ingredients are used in VOSEVI?
The U.S. prescribing information identifies the following tablet-core excipients:
- Copovidone
- Croscarmellose sodium
- Colloidal silicon dioxide
- Magnesium stearate
- Mannitol
- Microcrystalline cellulose
- Sodium lauryl sulfate
- Talc
The film coating contains:
- Ferrosoferric oxide
- Hypromellose
- Polyethylene glycol
- Red iron oxide
- Titanium dioxide
The excipients perform different technical functions. Microcrystalline cellulose and mannitol provide bulk and compactability. Copovidone supports binding. Croscarmellose sodium promotes tablet breakup. Sodium lauryl sulfate improves wetting of poorly water-soluble drug substances. Colloidal silicon dioxide supports flow and may reduce cohesion. Magnesium stearate provides lubrication, while talc is used in the coating system. Hypromellose and polyethylene glycol support film formation and plasticization.[1]
What excipient challenges does VOSEVI present?
VOSEVI presents a more demanding formulation problem than a conventional single-API immediate-release tablet.
High active load and tablet size
The three active ingredients account for 600 mg of the tablet before excipients and coating are considered. The formulation therefore has limited space for additional functional excipients. Suppliers that can improve compactability, flow, or tablet strength at low use levels have a stronger commercial position than suppliers offering only bulk filler capacity.
Solubility and dissolution control
Velpatasvir and voxilaprevir have limited aqueous solubility relative to highly soluble small molecules. Sodium lauryl sulfate and the selected disintegrant system help manage wetting and dispersion. A change in surfactant grade, particle size, specific surface area, or magnesium stearate blending time could affect dissolution.
For a generic manufacturer, matching assay is not enough. The product must maintain dissolution performance across tablet hardness, compression force, lubrication time, storage conditions, and fed-state testing. This creates demand for excipient suppliers with strong characterization packages and formulation support.
Multi-API segregation risk
The three active ingredients can differ in particle size, density, flow, and electrostatic behavior. These differences create blend-uniformity and segregation risks. Copovidone, microcrystalline cellulose, mannitol, and colloidal silicon dioxide must be selected and processed to produce a stable blend during transfer, compression, and packaging.
Excipient grades with controlled particle-size distribution, low variability, and reproducible bulk density can reduce process risk. Co-processed excipients may also have a role in development programs, although a generic manufacturer would need to show that the resulting formulation remains comparable to the reference product.
Which excipients offer the strongest commercial opportunities?
The commercial opportunity is concentrated in excipients that solve a measurable development or manufacturing problem.
| Excipient category |
VOSEVI relevance |
Commercial opportunity |
| Co-processed fillers and binders |
High active load and compression demands |
Reduce tablet weight, improve tensile strength, support direct compression |
| Surfactants and wetting agents |
Poor water solubility of some APIs |
Improve dissolution consistency and fed-state robustness |
| Superdisintegrants |
Rapid release from a dense tablet |
Control disintegration without excessive tablet expansion |
| Lubricants |
Blend and compression sensitivity |
Reduce ejection force while limiting dissolution impact |
| Colloidal silicon dioxide |
Flow and cohesion control |
Improve powder handling and blend uniformity |
| Film-coating systems |
Product identification and protection |
Supply ready-to-use color and coating systems |
| Analytical excipient services |
Multi-API formulation complexity |
Support extractables, impurities, particle-size, and dissolution studies |
Co-processed excipients
Co-processed microcrystalline cellulose and mannitol systems could compete with separate excipient additions if they improve flow, compactability, or tablet robustness. The commercial case is strongest when the excipient reduces the number of formulation variables or permits lower compression force.
The main barrier is regulatory comparability. A formulation developer cannot assume that a functionally equivalent excipient is interchangeable with the reference product. The change may affect dissolution, stability, impurity formation, or bioequivalence.
Surfactant systems
Sodium lauryl sulfate is a high-value formulation component in this context because it addresses wetting and dissolution. Opportunities exist for alternative surfactants or optimized grades, but substitution creates meaningful technical risk. Surfactant concentration can affect dissolution, gastrointestinal tolerability, tablet lubrication, and stability.
Suppliers can differentiate through low-peroxide grades, controlled moisture, defined particle size, and documentation for elemental impurities and residual solvents.
Ready-to-use film coatings
VOSEVI uses a colored film coating with iron oxides, titanium dioxide, hypromellose, and polyethylene glycol. Ready-to-use coating systems offer commercial value by reducing formulation work, improving color consistency, and simplifying scale-up.
The opportunity is particularly relevant for generic manufacturers seeking a close visual match. Color, opacity, coating weight, and surface finish can affect product identification and patient acceptance, although these factors generally do not provide a standalone barrier to generic entry.
How should a generic manufacturer approach VOSEVI excipient selection?
A generic development program should prioritize critical material attributes and critical process parameters rather than merely reproducing the listed excipient names.
Priority development sequence
- Establish API particle-size and solid-state controls for each active ingredient.
- Screen filler-binder systems for flow, compression, and tablet weight.
- Optimize sodium lauryl sulfate or an alternative wetting system against dissolution.
- Control lubricant concentration and blending time.
- Confirm disintegration performance at target hardness.
- Evaluate coating weight, color, moisture protection, and tablet dimensions.
- Test dissolution under multiple pH conditions and relevant fed-state conditions.
- Link excipient variability to bioequivalence risk before pivotal studies.
A generic formulation can use different inactive ingredients if the product satisfies applicable FDA requirements and demonstrates pharmaceutical equivalence and bioequivalence. The FDA inactive ingredient database can support precedent analysis, but it does not replace product-specific development or regulatory review.[2]
What patents protect VOSEVI, and do excipients create an entry barrier?
VOSEVI’s principal intellectual-property risk is associated with the active ingredients, combinations, methods of treatment, and manufacturing processes. Excipients generally do not create the primary exclusivity barrier for this product.
The Orange Book is the controlling public source for current U.S. patent listings and regulatory exclusivity. Patent status should be evaluated by listing, patent type, expiration, pediatric extensions, and any approved indications covered by method-of-use claims.[3]
Do excipient patents affect generic entry?
They can, but usually in narrower circumstances. An excipient patent could matter if it claims:
- A specific drug-excipient composition
- A defined dissolution or release profile
- A manufacturing process using a particular excipient grade
- A stabilized formulation
- A coating or tablet architecture tied to the product
A generic applicant may avoid such claims through a different formulation or process. The commercial importance of an excipient patent depends on claim scope, enforceability, design-around cost, and whether the patent is listed in the Orange Book.
What Paragraph IV risks exist?
A Paragraph IV applicant challenging an Orange Book-listed patent may argue that the patent is invalid, unenforceable, or not infringed. For VOSEVI, likely litigation exposure would center on active-ingredient composition, combination, treatment, or manufacturing claims rather than ordinary use of mannitol, microcrystalline cellulose, magnesium stearate, or hypromellose.
Excipient suppliers can still become relevant in litigation if their technical documents, formulation recommendations, or supply specifications are cited in a generic applicant’s development record. Supplier confidentiality, controlled technical disclosure, and documented freedom-to-operate analysis are therefore important.
When does VOSEVI lose exclusivity?
VOSEVI does not have biosimilar exclusivity because it is a small-molecule drug, not a biologic. Generic entry follows the abbreviated new drug application pathway rather than the biosimilar pathway.
The timing of U.S. generic entry depends on:
- FDA-listed patents
- Statutory exclusivity
- Paragraph IV certifications
- Any 30-month litigation stay
- Court decisions or settlements
- Patent-term adjustment and extension
- Product-specific regulatory requirements
The original product had five-year new chemical entity exclusivity associated with the combination product’s regulatory status, but that period has expired. Current commercial protection is therefore primarily patent-based rather than exclusivity-based.[1][3]
What FDA and global regulatory issues affect excipient commercialization?
Excipient suppliers must support more than basic compendial compliance.
Key documentation areas include:
- United States Pharmacopeia or equivalent monograph compliance
- Residual solvents
- Elemental impurities
- Nitrosamine risk where relevant
- Peroxide and oxidative impurity control
- Microbial quality
- Particle-size distribution
- Moisture and water activity
- Supplier-change notification
- Country-of-origin and manufacturing-site information
For European development, the European Medicines Agency product information and applicable European Pharmacopoeia standards provide the relevant regulatory framework.[4] Global manufacturers also need consistent excipient specifications across U.S., European, Japanese, and emerging-market supply chains.
Titanium dioxide and other coating components may attract jurisdiction-specific scrutiny. A supplier that offers region-specific coating alternatives, supported by color matching and stability data, can create a practical commercial advantage.
Which companies can capture value from the VOSEVI excipient market?
The opportunity is open to several supplier groups:
Functional excipient manufacturers
Companies supplying microcrystalline cellulose, mannitol, copovidone, croscarmellose sodium, colloidal silicon dioxide, and surfactants can compete through grade consistency, technical service, and supply assurance.
Coating suppliers
Ready-to-use film-coating manufacturers can target generic VOSEVI developers with color-matching services, scale-up support, and regulatory documentation.
Contract development and manufacturing organizations
CDMOs can offer formulation screening, blend-uniformity studies, dissolution optimization, analytical method development, and pilot-scale manufacturing. Their strongest proposition is reducing development time and bioequivalence risk.
Specialty analytical providers
Laboratories with experience in multi-API dissolution, solid-state characterization, excipient compatibility, and extractables can support both originator lifecycle management and generic development.
How strong is the commercial opportunity?
The opportunity is meaningful but specialized. VOSEVI is a high-value antiviral product, yet its market is smaller than broad primary-care products because hepatitis C treatment is finite and curative. Revenue exposure is concentrated in treatment cohorts, retreatment, and markets where access to pan-genotypic regimens is expanding.
Excipient suppliers should not model the opportunity solely on branded VOSEVI sales. The larger addressable market may come from:
- Generic and authorized-generic development
- Regional finished-dose manufacturers
- Combination-product platforms using similar direct-compression systems
- Reformulation and supply-chain localization
- Alternative coating systems
- Technical services for bioequivalence programs
The strongest commercial strategy is a bundled offer combining excipient supply, formulation support, analytical data, and regulatory documentation.
Key Takeaways
- VOSEVI is a 600 mg total-load, three-API immediate-release tablet containing sofosbuvir, velpatasvir, and voxilaprevir.
- Its listed excipients include copovidone, croscarmellose sodium, mannitol, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, talc, and a hypromellose-based film coating.
- The most valuable excipient functions are wetting, compactability, blend uniformity, disintegration, lubrication control, and coating reproducibility.
- Generic developers face greater formulation risk from dissolution and multi-API blend behavior than from ordinary excipient availability.
- VOSEVI is subject to generic, not biosimilar, competition.
- Patent risk is primarily tied to active ingredients, combinations, treatment methods, and manufacturing processes.
- Commercial opportunities are strongest in functional excipients, ready-to-use coatings, CDMO development, and analytical support.
- No excipient strategy should be evaluated without linking material attributes to dissolution, stability, and bioequivalence outcomes.
FAQs
Can a generic VOSEVI tablet use different excipients?
Yes. A generic manufacturer can use alternative inactive ingredients if the formulation meets FDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, quality, and acceptable safety.
Is sodium lauryl sulfate essential to VOSEVI?
The FDA label identifies sodium lauryl sulfate as an inactive ingredient. A generic manufacturer may evaluate alternatives, but substitution could affect wetting, dissolution, stability, and tolerability.
Are VOSEVI excipients protected by separate patents?
Ordinary use of common excipients generally does not create the main patent barrier. Product-specific formulation or process claims could create narrower risks and require an Orange Book and freedom-to-operate review.
Could VOSEVI be reformulated as a smaller tablet?
Potentially, but tablet-size reduction would require changes to API particle engineering, excipient selection, compression, coating, and dissolution control. Any reformulation would require product-specific regulatory and bioequivalence assessment.
What is the best supplier proposition for VOSEVI generics?
The strongest proposition combines controlled-grade excipients, formulation screening, dissolution support, scale-up data, coating technology, and regulatory documentation. Commodity pricing alone is unlikely to create a durable advantage.
References
-
U.S. Food and Drug Administration. (2024). Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) prescribing information. Gilead Sciences, Inc.
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
European Medicines Agency. (2017). Vosevi: EPAR product information. https://www.ema.europa.eu/ en/documents/product-information/vosevi-epar-product-information_en.pdf
